Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

150%

3 of 2 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1
7(87.5%)
Phase 2
1(12.5%)
8Total
Phase 1(7)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT00586924Phase 1Completed

A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia

Role: collaborator

NCT00587457Phase 1Terminated

A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia

Role: collaborator

NCT00640016Phase 2Terminated

A Study to Assess the Efficacy, Safety, and Tolerability of CAT-354 in Subjects With Asthma

Role: collaborator

NCT00043706Phase 1Completed

Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis

Role: collaborator

NCT00077493Phase 1Suspended

BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Role: collaborator

NCT00515892Phase 1Unknown

Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease

Role: lead

NCT00462189Phase 1Unknown

Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease

Role: lead

NCT00457860Phase 1Unknown

Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease

Role: lead

All 8 trials loaded